Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial

Authors

Tait D Shanafelt
Victoria Wang
Neil E Kay
Curtis A Hanson
Susan M O'Brien
Jacqueline C BarrientosFollow
Diane F Jelinek
Esteban BraggioFollow
Jose F Leis
Cong Christina Zhang
Steven CoutreFollow
Paul M BarrFollow
Amanda F CashenFollow
Anthony R Mato
Avina Singh
Michael P. Mullane, Advocate Aurora HealthFollow
Richard F Little
Harry P Erba
Richard M Stone
Mark Litzow
Martin S Tallman

Recommended Citation

Shanafelt TD, Wang V, Kay NE, et al. Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood. 2019;134(Supplement_1):33. doi: 10.1182/blood-2019-126824.

Affiliations

Aurora Cancer Care

Document Type

Article

PubMed ID

31723996